Zilia(AXIA-P)
RIO DE JANEIRO, BrazilBiotechnology
Focus: Zilia is a publicly-traded Brazilian biotech focused on ophthalmology devices for ocular biomarker assessment. The company operates at a modest scale with a single active job opening and limited commercial pipeline visibility.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Zilia?
AI assessmentHigh-risk, early-stage opportunity suitable only for career builders willing to bet on unproven clinical and commercial strategy in a nascent biotech.
Why Work Here
- Emerging player in ophthalmology with public market validation (ticker AXIA-P), offering early-stage exposure to a high-growth therapeutic area
- Device-based business model in biomarkers may provide differentiated career path versus traditional pharma
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Zilia Ocular
Retinal VascularClinical Trials (1)
NCT04408677Normative Data Collection Study of the Zilia Ocular for the Measurement of Oxygen Saturation in the Retina
N/AHelp build intelligence for Zilia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.